GlassScriptPhysician profile
Andrew Sherman
NPI 1104951540
$1,371.75
in general payments reported to CMS, 2019-2025
22 companies · $260 in 2025
The $260 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $513 · 2020: $50.41 · 2021: $101 · 2022: $53.35 · 2023: $240 · 2024: $153 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $641 · Education: $13.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $640.63 |
| Education | $13.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $355.47 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $173.95 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $91.82 | 2021-2025 | Dupixent |
| Inspire Medical Systems, INC. | $81.22 | 2023-2025 | Inspire |
| Mylan Specialty L.P. | $73.35 | 2019-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.29 | 2019-2022 | |
| Livanova USA, INC. | $62.64 | 2023 | Lifesparc |
| Amgen INC. | $51.10 | 2023-2025 | Tezspire |
| Electromed, INC. | $51.01 | 2019-2021 | |
| Grifols USA, LLC | $47.33 | 2019-2025 | Prolastin-C Liquid |
| Genentech USA, INC. | $45.22 | 2019-2023 | Xolair |
| Merck Sharp & Dohme LLC | $39.26 | 2019-2024 | Zerbaxa |
| Janssen Pharmaceuticals, INC | $36.08 | 2019 | |
| Mallinckrodt Enterprises LLC | $29.80 | 2019 | |
| Allergan, INC. | $27.62 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $25.94 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $25.57 | 2019-2021 | |
| Verona Pharma, INC. | $22.45 | 2025 | Ohtuvayre |
| Chiesi USA, INC. | $17.14 | 2019 | |
| Pulmonx Corporation | $16.74 | 2019 | |
| Circassia INC. | $16.55 | 2019 | |
| Shionogi INC | $13.20 | 2024 | Fetroja |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Sherman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.